Health technology company NuraLogix has developed artificial intelligence models to predict a person's risk for Type 2 diabetes.
Researchers at NuraLogix trained the AI tool to examine the facial blood flow patterns of thousands of patients with Type 2 diabetes. The tool had a prediction score of area under the curve greater than 0.80 compared to the Framingham model, which has an area under the curve around 0.70, according to the Aug. 10 NuraLogix news release.
"This technology is a disruptive tool for population health," Keith Thompson, MD, chief medical officer at NuraLogix, said in the news release. "We live in an Era where 1/2 of the globe is without access to health care, and in both developed and underdeveloped countries, there are shortages of Human Health resources. Traditional medical encounters are time consuming and costly for most people. Tools like this allow us to democratize NCD screening globally to regions in need by moving away from traditional physician face-to-face encounters and laboratory services, by allowing screening through the ubiquitous technology of smart phones."